Abstract
Purpose
Patients with relapse of recurrent glioma have a poor outcome and limited treatment options. The aim of this study is to investigate the clinical benefit and tolerability of weekly intravenous administration of carboplatin-based monotherapy in adult glioma patients who had progressed from previous chemotherapy lines based on temozolomide and nitrosoureas.
Methods
This was a single-arm, phase II study. Eligibility criteria included progressive or recurrent glioma after radiotherapy and chemotherapy-based treatments and Karnofsky performance status (KPS) > 60.
Results
Thirty-two patients (median age 43.5 years) were enrolled to receive weekly carboplatin monotherapy in an intravenous method of administration. The median duration of response was 7.3 months with an overall disease control rate of 31.3%. Median progression-free survival was 2.3 months while overall survival was 5.5 months. Pre-treatment with corticosteroids (i.e. dexamethasone) was associated to clinical benefit in 43.8% of patients. Patients achieving clinical benefit exhibited a longer progression-free survival (4.6 vs. 1.5 months; p > 0.001) and overall survival (7.9 vs. 3.2 months; p = 0.041) compared with those not achieving clinical benefit.
Conclusions
Our findings show that single agent, weekly, intravenous administration of carboplatin may have a role in patients with recurrent glioma and suggest that pre-treatment with corticosteroids may confer survival benefit.
Similar content being viewed by others
Change history
09 September 2019
In the original article, the names of authors Mariantonia Carosi and Tatiana Koudriavtseva were incorrectly captured, and author Francesco Cognetti's affiliation was incorrect. The information is correctly shown here.
References
Lapointe S, Perry A, Butowski NA (2018) Primary brain tumours in adults. Lancet 392:432–446
Crocetti E, Trama A, Stiller C et al (2012) Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer 48(10):1532–1542
Brandes AA, Finocchiaro G, Zagonel V et al (2016) AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. Neuro Oncol 18:1304–1312
Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507
Franceschi E, Lamberti G, Paccapelo A et al (2018) Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab? J Neurooncol 139:383–388
Prelaj A, Rebuzzi SE, Grassi M et al (2019) Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: survival across disease and treatment subgroup analysis and review of the literature. Mol Clin Oncol 10:58–66
Davis ME (2016) Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 20:S2–S8
Mrugala MM, Crew LK, Fink JR, Spence AM (2012) Carboplatin and bevacizumab for recurrent malignant glioma. Oncol Lett 4:1082–1086
Yung WK, Mechtler L, Gleason MJ (1991) Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9(5):860–864
Warnick RE, Prados MD, Mack EE et al (1994) A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 19(1):69–74
Reardon DA, Desjardins A, Peters KB et al (2012) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 107(1):155–164
Francesconi AB, Dupre S, Matos M et al (2010) Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. J Clin Neurosci 17(8):970–974
Field KM, Simes J, Nowak AK et al (2015) Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro Oncol 17:1504–1513
Pignata S, Breda E, Scambia G et al (2008) A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol 66:229–236
Jatoi A, Stella PJ, Hillman S et al (2003) Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (≥ 65 years of age): a phase II North Central Cancer Treatment Group study. Am J Clin Oncol. 26:441–447
Wesseling P, Capser D (2018) WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol 44:139–150
Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756
Wen PY, Macdonald DR, Reardon DA et al (2010) Updated Response Assessment Criteria for high grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972
Prelaj A, Rebuzzi SE, Grassi M et al (2019) Multimodal treatment for local recurrent malignant gliomas: re-surgery and/or re-irradiation followed by chemotherapy. Mol Clin Oncol 10:49–57
Taal W, Segers-van Rijn JM, Kros JM et al (2012) Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. J Neurooncol 108:195–200
Roberts N, Wadajkar AS, Winkles JA et al (2016) Repurposing platinum-based chemotherapies for multimodal treatment of glioblastoma. Oncoimmunology 5:e1208876
Ando M, Minami H, Ando Y et al (2000) Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 6:4733–4738
Murray LJ, Bridgewater CH, Levy D (2011) Carboplatin chemotherapy in patients with recurrent high-grade glioma. Clin Oncol 23:55–61
Pitter KL, Tamagno I, Alikhanyan K et al (2016) Corticosteroids compromise survival in glioblastoma. Brain 139:1458–1471
Wong ET, Lok E, Gautam S, Swanson KD (2015) Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer 113:232–241
Wong E, Swanson KD (2019) Dexamethasone-friend or foe for patients with glioblastoma? JAMA Neurol. 1:11. https://doi.org/10.1001/jamaneurol.2018.4530
Cenciarini M, Valentino M, Belia S et al (2019) Dexamethasone in glioblastoma multiforme therapy: mechanisms and controversies. Front Mol Neurosci 12:65
Acknowledgements
Editorial assistance was provided by Luca Giacomelli, PhD, Chiara Degirolamo, PhD, and Aashni Shah, from Polistudium (Milan, Italy); this assistance was supported by internal funds.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human and/or animal rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Regina Elena Institute, Rome, Italy) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Villani, V., Pace, A., Vidiri, A. et al. Phase II study of weekly carboplatin in pretreated adult malignant gliomas. J Neurooncol 144, 211–216 (2019). https://doi.org/10.1007/s11060-019-03223-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-019-03223-x